ABSTRACT
On the basis of a mu opioid receptor (MOR) homology model and the isosterism concept, three generations of 14-heteroaromatically substituted naltrexone derivatives were designed, synthesized, and evaluated as potential MOR-selective ligands. The first-generation ligands appeared to be MOR-selective, whereas the second and the third generation ones showed MOR/kappa opioid receptor (KOR) dual selectivity. Docking of ligands 2 (MOR selective) and 10 (MOR/KOR dual selective) to the three opioid receptor crystal structures revealed a nonconserved-residue-facilitated hydrogen-bonding network that could be responsible for their distinctive selectivity profiles. The MOR/KOR dual-selective ligand 10 showed no agonism and acted as a potent antagonist in the tail-flick assay. It also produced less severe opioid withdrawal symptoms than naloxone in morphine-dependent mice. In conclusion, ligand 10 may serve as a novel lead compound to develop MOR/KOR dual-selective ligands, which might possess unique therapeutic value for opioid addiction treatment.
Subject(s)
Drug Design , Naltrexone/chemical synthesis , Naltrexone/metabolism , Receptors, Opioid, kappa/metabolism , Receptors, Opioid, mu/metabolism , Animals , Behavior, Animal/drug effects , CHO Cells , Chemistry Techniques, Synthetic , Cricetinae , Cricetulus , Male , Mice , Models, Molecular , Naltrexone/chemistry , Naltrexone/pharmacology , Protein Conformation , Receptors, Opioid, kappa/chemistry , Receptors, Opioid, mu/chemistry , Substrate SpecificityABSTRACT
BACKGROUND: Leukemia inhibitory factor (LIF) is a cytokine with an essential role in the preparation of the endometrium for implantation. Previous studies demonstrated that PEGLA, a LIF receptor antagonist (LA) conjugated with polyethylene glycol (PEG), effectively prevents implantation in mice, identifying PEGLA as a potential contraceptive for women. STUDY DESIGN: Adult female cynomolgus macaques were used to determine the optimal route of administration to deliver PEGLA to the uterine endometrium. Endometrial explants were used to examine the ability of PEGLA to block LIF action at endometrial cells. RESULTS: Both intramuscular and subcutaneous PEGLA administration resulted in peak serum PEGLA 24 h after administration; serum PEGLA was detectable throughout the 144-h sampling period. In contrast, serum PEGLA was near or below the limit of detection after vaginal administration. After intramuscular administration, PEGLA was localized to both luminal and glandular epithelial cells of the uterine endometrium, and PEGLA was measurable in endometrial lysates. PEGLA administration reduced endometrial signal transducer and activator of transcription protein 3 (STAT3) phosphorylation in vivo and in vitro. PEGLA also blocked LIF's ability to elevate expression of cochlin, insulin-like growth factor-binding protein 3, vascular endothelial growth factor A, and cyclooxygenase-2 (also known as PTGS2) in endometrial explants in vitro. CONCLUSIONS: PEGLA was delivered to the non-human primate uterine endometrium with systemic administration, and PEGLA blocked LIF actions associated with implantation. Blocking LIF receptor activity with the antagonist PEGLA may prevent pregnancy in women and provide a novel alternative to currently-available hormonal and barrier contraceptives.
Subject(s)
Contraceptive Agents, Female/administration & dosage , Endometrium/drug effects , Gene Expression Regulation/drug effects , Leukemia Inhibitory Factor/antagonists & inhibitors , Polyethylene Glycols/administration & dosage , Administration, Intravaginal , Animals , Contraceptive Agents, Female/blood , Contraceptive Agents, Female/pharmacokinetics , Contraceptive Agents, Female/pharmacology , Endometrium/cytology , Endometrium/metabolism , Female , Immunohistochemistry , Injections, Intramuscular , Injections, Subcutaneous , Leukemia Inhibitory Factor/administration & dosage , Leukemia Inhibitory Factor/blood , Leukemia Inhibitory Factor/pharmacokinetics , Leukemia Inhibitory Factor/pharmacology , Macaca fascicularis , Metabolic Clearance Rate , Osmolar Concentration , Phosphorylation/drug effects , Polyethylene Glycols/pharmacokinetics , Polyethylene Glycols/pharmacology , Protein Processing, Post-Translational/drug effects , STAT3 Transcription Factor/metabolism , Signal Transduction/drug effects , Tissue Culture Techniques , Tissue DistributionABSTRACT
Prostaglandin E2 (PGE2) mediates many effects of the midcycle luteinizing hormone (LH) surge within the periovulatory follicle. Differential expression of the four PGE2 (EP) receptors may contribute to the specialized functions of each granulosa cell subpopulation. To determine if EP receptors are differentially expressed in granulosa cells, monkeys received gonadotropins to stimulate ovarian follicular development. Periovulatory events were initiated with human chorionic gonadotropin (hCG); granulosa cells and whole ovaries were collected before (0 h) and after (24-36 h) hCG to span the 40-h primate periovulatory interval. EP receptor mRNA and protein levels were quantified in granulosa cell subpopulations. Cumulus cells expressed higher levels of EP2 and EP3 mRNA compared with mural cells 36 h after hCG. Cumulus cell EP2 and EP3 protein levels also increased between 0 and 36 h after hCG. Overall, mural granulosa cells expressed low levels of EP1 protein at 0 h and higher levels 24-36 h after hCG. However, EP1 protein levels were higher in granulosa cells away from the follicle apex compared with apex cells 36 h after hCG. Higher levels of PAI-1 protein were measured in nonapex cells, consistent with a previous study showing EP1-stimulated PAI-1 protein expression in monkey granulosa cells. EP4 protein levels were low in all subpopulations. In summary, cumulus cells likely respond to PGE2 via EP2 and EP3, whereas PGE2 controls rupture of a specific region of the follicle via EP1. Therefore, differential expression of EP receptors may permit each granulosa cell subpopulation to generate a unique response to PGE2 during the process of ovulation.
Subject(s)
Granulosa Cells/metabolism , Macaca fascicularis/metabolism , Ovarian Follicle/metabolism , Ovulation/physiology , Receptors, Prostaglandin E/metabolism , Animals , Cumulus Cells/cytology , Cumulus Cells/metabolism , Female , Ovarian Follicle/cytology , Plasminogen Activator Inhibitor 1/metabolism , RNA, Messenger/metabolism , Tissue Plasminogen Activator/metabolismABSTRACT
Mu opioid receptor antagonists have clinical utility and are important research tools. To develop non-peptide and highly selective mu opioid receptor antagonist, a series of 14-O-heterocyclic-substituted naltrexone derivatives were designed, synthesized, and evaluated. These compounds showed subnanomolar-to-nanomolar binding affinity for the mu opioid receptor. Among them, compound 1 exhibited the highest selectivity for the mu opioid receptor over the delta and kappa receptors. These results implicated an alternative 'address' domain in the extracellular loops of the mu opioid receptor.
Subject(s)
Chemistry, Pharmaceutical/methods , Naltrexone/analogs & derivatives , Narcotic Antagonists/chemical synthesis , Receptors, Opioid, mu/antagonists & inhibitors , Receptors, Opioid, mu/chemistry , Binding, Competitive , Drug Design , Humans , Kinetics , Ligands , Molecular Conformation , Molecular Structure , Narcotic Antagonists/pharmacology , Nitrogen/chemistry , Peptides/chemistry , Protein Structure, TertiaryABSTRACT
Opioid receptor selective antagonists are important pharmacological probes in opioid receptor structural characterization and opioid agonist functional study. Thus far, a nonpeptidyl, highly selective and reversible mu opioid receptor (MOR) antagonist is unavailable. On the basis of our modeling studies, a series of novel naltrexamine derivatives have been designed and synthesized. Among them, two compounds were identified as leads based on the results of in vitro and in vivo assays. Both of them displayed high binding affinity for the MOR (K(i) = 0.37 and 0.55 nM). Compound 6 (NAP) showed over 700-fold selectivity for the MOR over the delta receptor (DOR) and more than 150-fold selectivity over the kappa receptor (KOR). Compound 9 (NAQ) showed over 200-fold selectivity for the MOR over the DOR and approximately 50-fold selectivity over the KOR. Thus these two novel ligands will serve as leads to further develop more potent and selective antagonists for the MOR.
Subject(s)
Analgesics/chemical synthesis , Morphinans/chemical synthesis , Naltrexone/analogs & derivatives , Naltrexone/chemical synthesis , Receptors, Opioid, mu/antagonists & inhibitors , Amino Acid Sequence , Analgesics/pharmacology , Analgesics, Opioid/antagonists & inhibitors , Analgesics, Opioid/pharmacology , Animals , Binding Sites , Binding, Competitive , CHO Cells , Cricetinae , Cricetulus , Drug Design , Ligands , Models, Molecular , Molecular Sequence Data , Morphinans/pharmacology , Morphine/antagonists & inhibitors , Morphine/pharmacology , Naltrexone/pharmacology , Radioligand Assay , Receptors, Opioid, delta/antagonists & inhibitors , Receptors, Opioid, kappa/antagonists & inhibitors , Receptors, Opioid, mu/agonists , Sequence Alignment , Structure-Activity RelationshipABSTRACT
The synthesis and enzyme inhibitor properties of reversible type B monoamine oxidase inhibitors are described. These compounds belong to the 5H-indeno[1,2-c]pyridazine family and possess a hydrophobic benzyloxy or 4,4,4-trifluorobutoxy side chain which, in contrast to a previous assignment, has been unambiguously located at C(8) of the heterocyclic moiety. Investigation of the regioisomeric structures establishes that substitution of the 5H-indeno[1,2-c]pyridazin-5-one core at C(7) vs C(8) dramatically influences the MAO-inhibiting properties of these compounds.